CoChat

Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Compelling evidence supports a causal role for lipoprotein(a) (Lp(a)) in cardiovascular disease. No pharmacotherapies directly targeting Lp(a) are currently available for clinical use. Here we report the discovery and development of olpasiran, a first-in-class, synthetic, double-stranded, N-acetylgalactosamine-conjugated small interfering RNA (siRNA) designed to directly inhibit LPA messenger RNA translation in hepatocytes and potently reduce plasma Lp(a) concentration. Olpasiran reduced Lp(a) concentrations in transgenic mice and cynomolgus monkeys in a dose-responsive manner, achieving up to over 80% reduction from baseline for 5-8 weeks after administration of a single dose. In a phase 1 dose-escalation trial of olpasiran (ClinicalTrials.gov: NCT03626662 ), the primary outcome was safety and tolerability, and the secondary outcomes were the change in Lp(a) concentrations and olpasiran pharmacokinetic parameters. Participants tolerated single doses of olpasiran well and experienced a 71-97% reduction in Lp(a) concentration with effects persisting for several months after administration of doses of 9 mg or higher. Serum concentrations of olpasiran increased approximately dose proportionally. Collectively, these results validate the approach of using hepatocyte-targeted siRNA to potently lower Lp(a) in individuals with elevated plasma Lp(a) concentration.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01634-w

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Nugent, A., Gray, J., Gorby, L. & Moriarty, P. Lipoprotein apheresis: first FDA indicated treatment for elevated lipoprotein (a). J. Clin. Cardiol. 1, 16–21 (2019).

Cited by

See all 239

Metadata

Authors
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., Haldar, S. M., Sohn, W., Wang, H., Elliott-Davey, M., Rock, B. M., Pei, T., Homann, O., Hellawell, J., & Watts, G. F.
Affiliations
  • Jacksonville Center for Clinical Research (US)
  • University of Kansas Medical Center (US)
  • Orange County Research Center (US)
  • NYU Langone Health (US)
  • Amgen (United States) (US)
  • Arrowhead Pharmaceuticals (United States) (US)
  • The University of Western Australia (AU)
Corresponding author
Koren, Michael J.
Venue
Nature Medicine
Published
2022-01
Volume
28
Issue
1
Pages
96-103
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4206591430
Cited by
239
References
49
Citations by year
2026: 26 · 2025: 41 · 2024: 49 · 2023: 70 · 2022: 53
FWCI
50.83
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
  • 社会経済史学
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
olpasiran, lipoprotein(a), siRNA therapeutics, cardiovascular disease, coronary artery disease, Lp(a) lowering, pharmacokinetics, safety and tolerability, preclinical models
MeSH terms
Adult, Animals, Female, Humans, Hyperlipidemias, Macaca fascicularis, Male, Mice, Transgenic, Middle Aged, Lipoprotein(a), RNA, Small Interfering, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). https://app.cochat.ai/papers/10.1038/s41591-021-01634-w
The paper
Koren, M. J., Moriarty, P. M., Baum, S. J., Neutel, J., Hernandez-Illas, M., Weintraub, H. S., Florio, M., Kassahun, H., Melquist, S., Varrieur, T., Haldar, S. M., Sohn, W., Wang, H., Elliott-Davey, M., Rock, B. M., Pei, T., Homann, O., Hellawell, J., & Watts, G. F. (2022). Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nature Medicine. https://doi.org/10.1038/s41591-021-01634-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.